Journal article
What F-18-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?
Guy-Anne Turgeon, Amir Iravani, Tim Akhurst, Alexis Beaulieu, Jason W Callahan, Mathias Bressel, Aidan J Cole, Sarah J Everitt, Shankar Siva, Rodney J Hicks, David L Ball, Michael P Mac Manus
JOURNAL OF NUCLEAR MEDICINE | SOC NUCLEAR MEDICINE INC | Published : 2019
Abstract
The optimal methodology for defining response with 18F-FDG PET after curative-intent chemoradiation for non-small cell lung cancer (NSCLC) is unknown. We compared survival outcomes according to the criteria of the European Organization for Research and Treatment of Cancer (EORTC), PERCIST 1.0, the Peter Mac metabolic visual criteria, and the Deauville criteria, respectively. Methods: Three prospective trials of chemoradiation for NSCLC, involving baseline and posttreatment 18F-FDG PET/CT imaging, were conducted between 2004 and 2016. Responses were categorized as complete metabolic response (CMR), partial metabolic response, stable metabolic disease, or progressive metabolic disease. Cox pro..
View full abstractGrants
Awarded by National Health and Medical Research Council
Awarded by Cancer Australia Priority-driven Collaborative Cancer Research Scheme
Funding Acknowledgements
The <SUP>18</SUP>F-FLT/<SUP>18</SUP>F-FDG study (ACTRN12611001283965) was supported by the National Health and Medical Research Council (APP1003895) and the Victorian Cancer Agency. The <SUP>68</SUP>Ga-ventilation/perfusion PET study (U1111-1138-4421) was supported by the National Health and Medical Research Council (APP1038399) and the Cancer Australia Priority-driven Collaborative Cancer Research Scheme (project 1060919). David L. Ball has an advisory role for Pfizer Australia. Rodney J. Hicks has ownership interest in Telix Radiopharmaceuticals. Shankar Siva has an advisory role for Astellas and Janssen, receives research funding and is on the speakers' bureau of Varian Medical Systems and Merck, Sharp, and Dohme, and receives travel and accommodations expenses from Bristol-Meyer-Squibb. No other potential conflict of interest relevant to this article was reported.